Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis

Hu，Peng1,2; Huang，Jun3; Lu，Yi4; Zheng，Murui5; Li，Haiyi6; Duan，Xueru1; Deng，Hai7; Zhao，Wenjing8; Liu，Xudong2

2022-08-22

10.3389/fcvm.2022.952430

Frontiers in Cardiovascular Medicine   影响因子和分区

2297-055X

2297-055X

Background: Sex hormones are associated with many cardiovascular risk factors, but their effects on atrial fibrillation (AF) incidence remain unclear. This systematic review and meta-analysis aimed to evaluate the association of circulating sex hormones with AF risk by pooling available data from observational studies. Methods: A systematic literature search for pertinent articles with case-control and cohort designs was conducted via five databases up to 7 July 2021. A meta-analysis with six cohort studies was conducted separately on men and women. Adjusted relative risk (RR) with a 95% confidence interval (CI) was derived by comparing the highest with the lowest levels of a specific sex hormone and by using a random-effect or fixed-effect model. Heterogeneity was tested using the I statistic and the Q-test. Results: A total of six cohort studies and four case-control studies were included. In a meta-analysis of cohort studies, dehydroepiandrosterone sulfate (DHEAS) was associated with a decreased risk of AF in men (RR: 0.729, 95% CI: 0.559–0.952, I = 50.0%, P = 0.157) after combining results from two cohort studies; total testosterone was not associated with any risk of AF in men and postmenopausal women, and AF risk was not associated with estradiol in men after synthesizing available studies. Conclusion: This study indicates that a higher endogenous DHEAS level was associated with a lower AF risk in men, whereas total testosterone and estradiol were not associated with AF risk. Longitudinal studies with multiple monitoring are needed to further promulgate the relationship between various circulating sex hormones and AF risk.

atrial fibrillation dehydroepiandrosterone sulfate estradiol sex hormones total testosterone

SCI

英语

通讯

Guangdong Provincial Key RD Program[2018YFE0208000] ; Medical Science and Technology Research Fund of Guangdong Province[2019B020230004] ; Science and Technology Program of Guangzhou City[A2021129] ; Guangdong Basic and Applied Basic Research Foundation[202102080404] ; [2022A1515010686]

Cardiovascular System & Cardiology

Cardiac & Cardiovascular Systems

WOS:000873977800001

FRONTIERS MEDIA SA

2-s2.0-85137891489

Scopus

1.Department of Epidemiology,School of Public Health,Sun Yat-sen University,Guangzhou,China
2.School of Public Health,Guangdong Pharmaceutical University,Guangzhou,China
3.Department of Geriatrics,Institute of Geriatrics,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Science,Guangzhou,China
4.Health Effects Institute,Boston,United States
5.Guangzhou Center for Disease Control and Prevention,Guangzhou,China
6.Shantou University Medical College,Shantou,China
7.Department of Cardiology,Guangdong Cardiovascular Institute,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Science,Guangzhou,China
8.School of Public Health and Emergency Management,Southern University of Science and Technology,Shenzhen,China

Hu，Peng,Huang，Jun,Lu，Yi,et al. Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis[J]. Frontiers in Cardiovascular Medicine,2022,9.

Hu，Peng.,Huang，Jun.,Lu，Yi.,Zheng，Murui.,Li，Haiyi.,...&Liu，Xudong.(2022).Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis.Frontiers in Cardiovascular Medicine,9.

Hu，Peng,et al."Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis".Frontiers in Cardiovascular Medicine 9(2022).